{"id":"W4360614721","doi":"10.1136/ejhpharm-2023-eahp.6","title":"NP-006 Immunotherapy in second-line treatment of non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bausch Health","keywords":"Nivolumab; Medicine; Atezolizumab; Pembrolizumab; Internal medicine; Immunotherapy; Oncology; Lung cancer; Progression-free survival; Retrospective cohort study; Cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006974719,0.00007966921,0.0002709357,0.0001525515,0.0001478499,0.0003593301,0.0001591741,0.0002197727,0.001479055],"category_scores_gemma":[0.0006831107,0.00003517109,0.0002646819,0.0002982867,0.0001799245,0.0001895523,0.000183612,0.0002521971,0.0002288577],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002615085,"about_ca_system_score_gemma":0.0004498012,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005585531,"about_ca_topic_score_gemma":0.0008934707,"domain_scores_codex":[0.9997236,0.0001184736,0.0000289992,0.00003808644,0.00006157648,0.0000292033],"domain_scores_gemma":[0.9993253,0.0001515519,0.0003596494,0.00002274082,0.0000404476,0.0001003468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01067323,0.001600814,0.7934127,0.0006977635,0.0002426611,0.0008452126,0.0001620653,0.0006424169,0.009190095,0.0002262292,0.002239247,0.1800676],"study_design_scores_gemma":[0.001326696,0.02077356,0.9518282,0.000153956,0.0002228289,0.005056341,0.0002375558,0.001694959,0.005341423,0.0002628771,0.01308638,0.00001510637],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"methods","genre_scores_codex":[0.9913744,0.006086915,0.0002158919,0.0002233709,0.0000332548,0.00005521108,0.0004270489,0.000008405097,0.001575533],"genre_scores_gemma":[0.9978616,0.00100541,0.0002455756,0.0001235385,0.00006084768,0.00003134821,0.0003868025,0.00000162208,0.0002832095],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.001479055,"threshold_uncertainty_score":0.00494796,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01950030349828039,"score_gpt":0.3047197507621534,"score_spread":0.2852194472638729,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}